Access
To read this story in full you will need to login or make a payment (see right).
News Feature
Nature 449, 274-276 (20 September 2007) | doi:10.1038/449274a; Published online 19 September 2007
Biotechs go generic: The same but different
Heidi Ledford1
- Heidi Ledford writes for Nature from Boston.
Abstract
As several lucrative protein-based drugs are poised to go off patent, makers of biopharmaceuticals argue that their products are too complex to be reproduced as generics. Heidi Ledford investigates how close 'biosimilar' drugs can get to the original.
In 2006, Craig Wheeler, then president of Chiron BioPharmaceuticals in Emeryville, California, received a call from across the country that would challenge his perspective on the biotechnology industry. Momenta Pharmaceuticals, a small firm in Cambridge, Massachusetts, was looking for a new chief executive.
To read this story in full you will need to login or make a payment (see right).
